Keros Therapeutics: A Potential Dart Throw [Seeking Alpha]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Seeking Alpha
KROS holds $690 million in cash, and plans a $375 million shareholder return, and Keros could benefit from over $1.1 billion in potential Takeda milestones. Elritercept, now out-licensed to TAK, shows promising Phase 2 data for myelodysplastic syndromes and drives near-term revenue via milestones and royalties. With KER-065 years from pivotal data and limited pipeline, KROS stock is a speculative play suitable only for aggressive investors seeking high-risk opportunities. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » gopixa/iStock via Getty Images Shares of biopharmaceutical concern Keros Therapeutics, Inc. NASDAQ: KROS ) are trading at a small discount to cash after officially abandoning its cibotercept program, leaving it one wholly owned asset. With a 2025 that has so far featured More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific cov
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender OfferGlobeNewswire
- Keros Therapeutics Announces Preliminary Results of Tender OfferGlobeNewswire
KROS
Earnings
- 11/5/25 - Beat
KROS
Sec Filings
- 11/20/25 - Form SC
- 11/19/25 - Form SC
- 11/18/25 - Form SCHEDULE
- KROS's page on the SEC website